CTOs on the Move

Amer Assoc of Electrodiagnostic Medicine

www.aaem.net

 
Amer Assoc of Electrodiagnostic Medicine is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aaem.net
  • 421 1st Ave SW Ste 300e
    Rochester, MN USA 55902
  • Phone: 250.957.2314

Executives

Name Title Contact Details

Similar Companies

Medrad

MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems,

Insitus Biotechnologies

Insitus Biotechnologies is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spring Works

Spring Works is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

Aravive

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.